Crossmark

Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system

Published Online: 2024-08-12

Published Print: 2024-10

Authors

Xia, Chunyong

Liu, Zhijing

Liu, Jie

Lin, Li

Chen, Maohua
License Information

Text and Data Mining valid from 2024-08-12

Version of Record valid from 2024-08-12
More Information

Article History

Received: 15 May 2024

Accepted: 11 July 2024

First Online: 12 August 2024

Declarations

:

: The authors declare no competing interests.

: The FAERS database contains anonymized patient information. The Hospital Ethics Committee has confirmed that no ethical approval was required.

Document is current